Literature DB >> 23806772

Mice engrafted with human fetal thymic tissue and hematopoietic stem cells develop pathology resembling chronic graft-versus-host disease.

Jennifer L Lockridge1, Ying Zhou, Yusof A Becker, Shidong Ma, Shannon C Kenney, Peiman Hematti, Christian M Capitini, William J Burlingham, Annette Gendron-Fitzpatrick, Jenny E Gumperz.   

Abstract

Chronic graft-versus-host disease (cGVHD) is a significant roadblock to long-term hematopoietic stem cell (HSC) transplantation success. Effective treatments for cGVHD have been difficult to develop, in part because of a paucity of animal models that recapitulate the multiorgan pathologies observed in clinical cGVHD. Here we present an analysis of the pathology that occurs in immunodeficient mice engrafted with human fetal HSCs and implanted with fragments of human fetal thymus and liver. Starting at time points generally later than 100 days post-transplantation, the mice developed signs of illness, including multiorgan cellular infiltrates containing human T cells, B cells, and macrophages; fibrosis in sites such as lungs and liver; and thickened skin with alopecia. Experimental manipulations that delayed or reduced the efficiency of the HSC engraftment did not affect the timing or progression of disease manifestations, suggesting that pathology in this model is driven more by factors associated with the engrafted human thymic organoid. Disease progression was typically accompanied by extensive fibrosis and degradation of the thymic organoid, and there was an inverse correlation of disease severity with the frequency of FoxP3(+) thymocytes. Hence, the human thymic tissue may contribute T cells with pathogenic potential, but the generation of regulatory T cells in the thymic organoid may help to control these cells before pathology resembling cGVHD eventually develops. This model thus provides a new system to investigate disease pathophysiology relating to human thymic events and to evaluate treatment strategies to combat multiorgan fibrotic pathology produced by human immune cells.
Copyright © 2013 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chronic GVHD; Humanized mouse

Mesh:

Year:  2013        PMID: 23806772      PMCID: PMC3755109          DOI: 10.1016/j.bbmt.2013.06.007

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  25 in total

Review 1.  HIV-1 immunopathogenesis in humanized mouse models.

Authors:  Liguo Zhang; Lishan Su
Journal:  Cell Mol Immunol       Date:  2012-04-16       Impact factor: 11.530

2.  Factors affecting thymic function after allogeneic hematopoietic stem cell transplantation.

Authors:  K Weinberg; B R Blazar; J E Wagner; E Agura; B J Hill; M Smogorzewska; R A Koup; M R Betts; R H Collins; D C Douek
Journal:  Blood       Date:  2001-03-01       Impact factor: 22.113

Review 3.  Ocular graft-versus-host disease.

Authors:  Michelle Hessen; Esen K Akpek
Journal:  Curr Opin Allergy Clin Immunol       Date:  2012-10

4.  Efficient peripheral construction of functional human regulatory CD4(+)CD25(high)Foxp3(+) T cells in NOD/SCID mice grafted with fetal human thymus/liver tissues and CD34(+) cells.

Authors:  Kaizhong Duan; Baojun Zhang; Wenying Zhang; Yunan Zhao; Yanyan Qu; Chenming Sun; Yong Zhao
Journal:  Transpl Immunol       Date:  2011-08-11       Impact factor: 1.708

Review 5.  Late pulmonary complications after allogeneic hematopoietic stem cell transplantation: diagnosis, monitoring, prevention, and treatment.

Authors:  Andrea Bacigalupo; Jason Chien; Giovanni Barisione; Steven Pavletic
Journal:  Semin Hematol       Date:  2012-01       Impact factor: 3.851

6.  Low serum thymic hormone levels in patients with chronic graft-versus-host disease.

Authors:  K Atkinson; G S Incefy; R Storb; K M Sullivan; T Iwata; M Dardenne; H D Ochs; R A Good; E D Thomas
Journal:  Blood       Date:  1982-05       Impact factor: 22.113

7.  Factors affecting reconstitution of the T cell compartment in allogeneic haematopoietic cell transplant recipients.

Authors:  P R Fallen; L McGreavey; J A Madrigal; M Potter; M Ethell; H G Prentice; A Guimarães; P J Travers
Journal:  Bone Marrow Transplant       Date:  2003-11       Impact factor: 5.483

8.  Chronic graft-versus-host disease (GVHD) as a model for scleroderma. I. Description of model systems.

Authors:  B D Jaffee; H N Claman
Journal:  Cell Immunol       Date:  1983-04-01       Impact factor: 4.868

9.  The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function.

Authors:  J M McCune; R Namikawa; H Kaneshima; L D Shultz; M Lieberman; I L Weissman
Journal:  Science       Date:  1988-09-23       Impact factor: 47.728

Review 10.  Advances in graft-versus-host disease biology and therapy.

Authors:  Bruce R Blazar; William J Murphy; Mehrdad Abedi
Journal:  Nat Rev Immunol       Date:  2012-05-11       Impact factor: 53.106

View more
  24 in total

Review 1.  Use of Humanized Mice to Study the Pathogenesis of Autoimmune and Inflammatory Diseases.

Authors:  Iurii Koboziev; Yava Jones-Hall; John F Valentine; Cynthia Reinoso Webb; Kathryn L Furr; Matthew B Grisham
Journal:  Inflamm Bowel Dis       Date:  2015-07       Impact factor: 5.325

2.  Full Length Single Chain Fc Protein (FLSC IgG1) as a Potent Antiviral Therapy Candidate: Implications for In Vivo Studies.

Authors:  Olga S Latinovic; Sandra Medina-Moreno; Kate Schneider; Neelakshi Gohain; Juan Zapata; Marzena Pazgier; Marvin Reitz; Joseph Bryant; Robert R Redfield
Journal:  AIDS Res Hum Retroviruses       Date:  2015-06-22       Impact factor: 2.205

Review 3.  Humanized mouse models of immunological diseases and precision medicine.

Authors:  Leonard D Shultz; James Keck; Lisa Burzenski; Sonal Jangalwe; Shantashri Vaidya; Dale L Greiner; Michael A Brehm
Journal:  Mamm Genome       Date:  2019-03-07       Impact factor: 2.957

4.  Humanizing the mouse immune system to study splanchnic organ inflammation.

Authors:  Brianyell McDaniel Mims; Matthew B Grisham
Journal:  J Physiol       Date:  2018-04-25       Impact factor: 5.182

5.  Role of Wild-type and Recombinant Human T-cell Leukemia Viruses in Lymphoproliferative Disease in Humanized NSG Mice.

Authors:  Devra D Huey; Brad Bolon; Krista M D La Perle; Priya Kannian; Steven Jacobson; Lee Ratner; Patrick L Green; Stefan Niewiesk
Journal:  Comp Med       Date:  2018-02-01       Impact factor: 0.982

6.  Human Mesenchymal Stem Cell-Educated Macrophages Are a Distinct High IL-6-Producing Subset that Confer Protection in Graft-versus-Host-Disease and Radiation Injury Models.

Authors:  Myriam N Bouchlaka; Andrea B Moffitt; Jaehyup Kim; John A Kink; Debra D Bloom; Cassandra Love; Sandeep Dave; Peiman Hematti; Christian M Capitini
Journal:  Biol Blood Marrow Transplant       Date:  2017-02-28       Impact factor: 5.742

Review 7.  The Development of Next-generation PBMC Humanized Mice for Preclinical Investigation of Cancer Immunotherapeutic Agents.

Authors:  Y Maurice Morillon; Ariana Sabzevari; Jeffrey Schlom; John W Greiner
Journal:  Anticancer Res       Date:  2020-10       Impact factor: 2.480

8.  Current Concepts and Advances in Graft-Versus-Host Disease Immunology.

Authors:  Geoffrey R Hill; Brian C Betts; Victor Tkachev; Leslie S Kean; Bruce R Blazar
Journal:  Annu Rev Immunol       Date:  2021-01-11       Impact factor: 28.527

9.  A novel clinically relevant graft-versus-leukemia model in humanized mice.

Authors:  Bei Jia; Chenchen Zhao; Michael Bayerl; Hiroko Shike; David F Claxton; W Christopher Ehmann; Shin Mineishi; Todd D Schell; Pan Zheng; Yi Zhang; Leonard D Shultz; K Sandeep Prabhu; Robert F Paulson; Hong Zheng
Journal:  J Leukoc Biol       Date:  2021-05-31       Impact factor: 4.962

10.  Development of Mast Cell and Eosinophil Hyperplasia and HLH/MAS-Like Disease in NSG-SGM3 Mice Receiving Human CD34+ Hematopoietic Stem Cells or Patient-Derived Leukemia Xenografts.

Authors:  Laura J Janke; Denise M Imai; Heather Tillman; Rosalinda Doty; Mark J Hoenerhoff; Jiajie J Xu; Zachary T Freeman; Portia Allen; Natalie Wall Fowlkes; Ilaria Iacobucci; Kirsten Dickerson; Charles G Mullighan; Peter Vogel; Jerold E Rehg
Journal:  Vet Pathol       Date:  2020-11-19       Impact factor: 2.221

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.